ticker

Fighting Spam

vanya
24 Feb, 2003
New York City

As spam - or unsolicited e-mail - continues to plague corporate networks, the army of vendors offering defences is growing as well. Will fighting spam become big business?

Biotechs on the Mend; Biogen Triumphs

kalina
16 Feb, 2003
New York City

Despite the many uncertainties associated with the biotech sector, there are several worthy investment choices. Biogen, which got two regulatory approvals lately, is one of them.

Will 2003 Bring an Uptick in the VC Business?

vanya
10 Feb, 2003
New York City

Last year was a sobering one for venture capitalists as investment activity finished at a pace that was the slowest in nearly five years. Will 2003 be better for the VC business?

Johnson & Johnson: Quality at Good Price

kalina
03 Feb, 2003
New York City

Having managed to grow even during an economic slowdown, healthcare and pharma industry top dog Johnson & Johnson, is poised to attain greater heights in the long run.

Business Intelligence Gathers Momentum

vanya
27 Jan, 2003
New York City

Investors have become skittish about software makers, but it might be smart to keep an eye on business intelligence

JP Morgan Meet Puts Biotechs in the Spotlight

kalina
20 Jan, 2003
New York City

The JP Morgan Healthcare meet did little to boost sector stocks, which were already negatively impacted by a slew of bad news. But the market climate is likely to get better soon.

When Will Nanotech Bring in the Big Bucks?

vanya
14 Jan, 2003
New York City

Nanotechnology has recently emerged as one of the most hotly debated topics around the globe. But, is the

Biotechs: A Bleak 2002; Will 2003 Be Better?

kalina
09 Jan, 2003
New York City

After a dismal 2001, biotech stocks ended 2002 on a much weaker note. Still, industry fundamentals seem to be improving and some stocks may give patient investors reasons to cheer

2002 IPO Crop Thin, but Outperforms Market

vanya
30 Dec, 2002
New York City

Although the bleak environment of the broader market in 2002 extended to the IPO arena too, there still was good news for investors as new issues outperformed the market as a whole

Biotechs Poised for Recovery in 2003

kalina
26 Dec, 2002
New York City

Hopes of an imminent biotech-sector recovery were fanned following news that two vital drugs had gained panel recommendations, placing them on the threshold of regulatory approval.

Online Banking Clicks On

vanya
17 Dec, 2002
New York City

Online banking failed to live up to its hype, but today, consumers have begun warming up to the idea of banking on the Web. Which players are set to gain from the renewed interest?

Biotech Sector: Consolidation on Cards

kalina
16 Dec, 2002
New York City

The growing number of cash-hungry biotechs is bound to incite a wave of deals leading to sector consolidation. Biotech leader Gilead Sciences has already benefited from such a deal

Luxury Hotel Chains Poised for Recovery

iliana
10 Dec, 2002
New York City

Luxury hotels Starwood and Orient-Express have suffered sorely due to the economic downturn. But, their strong brand presence and margins give them plenty of upside potential.

ASH Meet May Trigger Biotech Rally

kalina
04 Dec, 2002
New York City

The upcoming ASH meeting has been attracting the attention of not only scientists but also investors. This interest may prove to be a boon for biotech stocks in the short run.

Finding Opportunities in P&C Insurance

vanya
03 Dec, 2002
New York City

The Sept. 11 attacks and the market downturn have taken their toll on the insurance business, but investors may still find good opportunities in some property and casualty insurers

Market Update